ClinicalTrials.gg
CompletedNCT02572752Updated Jan 5, 2017Results posted

Relative Bioavailability of 2 Oral Formulations of Nintedanib

A Phase 1 interventional study of Nintedanib and Nintedanib in Healthy, sponsored by Boehringer Ingelheim. Completed at 1 site in Germany. Open to male participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-01-05.

Sponsored by Boehringer Ingelheim · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
70
Allocation
Randomized
Ages
18 Years to 50 Years
Sex
Male
01

Study summary

To establish the bioequivalence of 1 soft gelatine capsule containing 200 mg nintedanib compared to 2 soft gelatine capsules containing 100 mg nintedanib

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.

Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy male subjects according to the investigators assessment, based on a complete medical history including a physical examination, vital signs (BP, PR), 12-lead , and clinical laboratory tests.
  2. Age of 18 to 50 years (incl.)
  3. Body weight of at least 70 kg
  4. of 21 to 31 kg/m2 (incl.)
  5. Signed and dated written prior to admission to the study in accordance with GCP and local legislation
  6. Male subjects, who are willing to use a medically acceptable method of during the first 3 months after administration of nintedanib. Acceptable methods of contraception for use by male volunteers include sexual abstinence, a vasectomy performed at least 1 year prior to dosing and barrier contraception (condom). Subjects, who are not vasectomised or sexually abstinent have to ensure that an additional acceptable method of contraception will be used by his female partner such as IUD (intrauterine device), surgical sterilisation (including hysterectomy), hormonal contraception (e.g. implants, injectables, combined oral or vaginal contraceptives) that started at least 2 months prior to first nintedanib administration, or barrier method (e.g. diaphragm with spermicide).

Exclusion criteria

Exclusion criteria:

  1. Any finding in the medical examination (including BP, PR or ) is deviating from normal and judged as by the investigator
  2. Repeated measurement of systolic blood pressure outside the range of 90 to 140 mmHg, diastolic blood pressure outside the range of 50 to 90 mmHg, or pulse rate outside the range of 45 to 90 bpm
  3. Any laboratory value outside the reference range that the investigator considers to be of clinical relevance
  4. Any evidence of a concomitant disease judged as clinically relevant by the investigator
  5. Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders
  6. Cholecystectomy and/or surgery of the gastrointestinal tract that could interfere with the pharmacokinetics of the trial medication (except appendectomy and simple hernia repair)
  7. Diseases of the central nervous system (including but not limited to any kind of seizures or stroke), and other relevant neurological or psychiatric disorders
  8. History of relevant orthostatic hypotension, fainting spells, or blackouts
  9. Chronic or relevant acute infections
  10. History of relevant allergy or (including allergy to the trial medication or its )
  11. Intake of drugs with a long half-life (more than 24 h) within 30 days or less than 10 half-lives of the respective drug prior to administration of trial medication
  12. Within 10 days prior to administration of trial medication, use of drugs that might reasonably influence the results of the trial
  13. Participation in another trial where an drug has been administered within 60 days prior to planned administration of trial medication
  14. Smoker (more than 10 cigarettes or 3 cigars or 3 pipes per day)
  15. Inability to refrain from smoking on specified trial days
  16. Alcohol abuse (consumption of more than 30 g per day for males)
  17. Drug abuse or positive drug screening
  18. Blood donation of more than 100 mL within 30 days prior to administration of trial medication or intended donation during the trial
  19. Intention to perform excessive physical activities within one week prior to administration of trial medication or during the trial
  20. Inability to comply with dietary regimen of trial site
  21. Subject is assessed as unsuitable for inclusion by the investigator, for instance, because considered not able to understand and comply with study requirements, or has a condition that would not allow safe participation in the study
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
70 participants (actual)

Study arms

  • Experimental
    Treatment T (Test)

    Nintedanib, 1 capsule, oral with 240 mL of water

    Drug: Nintedanib

  • Experimental
    Treatment R - 1 (Reference)

    Nintedanib, 2 capsules, oral with 240 mL of water

    Drug: Nintedanib

  • Experimental
    Treatment R - 2 (Reference)

    Nintedanib, 2 capsules, oral with 240 mL of water

    Drug: Nintedanib

Interventions

  • 1 soft gelatine capsule, single dose, oral

  • Nintedanib, 2 soft gelatine capsules, single dose, oral

  • Also known as: Nintedanib, 2 soft gelatine capsules, single dose, oral

06

What researchers measure

Primary outcomes

  1. AUC0-tz

    Area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the last quantifiable data point (AUC0-tz). The unadjusted geometric mean (gMean) and geometric coefficient variation (gCV) was calculated for Test treatment (T), Reference treatment 1 (R1) and Reference treatment 2 (R2) separately.

    Time frame: -1:00 hour(h) before drug administration and 0:30h, 1:00h, 1:30h, 2:00h, 2:30h, 3:00h, 3:30h, 4:00h, 4:30h, 5:00h, 5:30h, 6:00h, 7:00h, 8:00h, 10:00h, 12:00h, 24:00h, 34:00h, 48:00h and 72:00h after drug administration.

  2. Cmax

    Maximum measured concentration of the analyte in plasma (Cmax). The unadjusted geometric mean (gMean) and geometric coefficient variation (gCV) was calculated for Test treatment (T), Reference 1 treatment (R1) and Reference 2 treatment (R2) separately.

    Time frame: -1:00 hour(h) before drug administration and 0:30h, 1:00h, 1:30h, 2:00h, 2:30h, 3:00h, 3:30h, 4:00h, 4:30h, 5:00h, 5:30h, 6:00h, 7:00h, 8:00h, 10:00h, 12:00h, 24:00h, 34:00h, 48:00h and 72:00h after drug administration.

Secondary outcomes

  1. AUC0-inf

    Area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity (AUC0-inf). The unadjusted geometric mean (gMean) and geometric coefficient variation (gCV) was calculated for Test treatment (T), Reference 1 treatment (R1) and Reference 2 treatment (R2) separately.

    Time frame: -1:00 hour(h) before drug administration and 0:30h, 1:00h, 1:30h, 2:00h, 2:30h, 3:00h, 3:30h, 4:00h, 4:30h, 5:00h, 5:30h, 6:00h, 7:00h, 8:00h, 10:00h, 12:00h, 24:00h, 34:00h, 48:00h and 72:00h after drug administration.

07

Results

Posted Jan 5, 2017

Participant flow

Period 1 Including Washout
Participant flow — Period 1 Including Washout
MilestoneNin 2x100 mg(R1) / Nin 2x100 mg(R2) / Nin 1x200 mg(T)Nin 2x100 mg(R1) / Nin 1x200 mg(T) / Nin 2x100 mg(R2)Nin 1x200 mg(T) / Nin 2x100 mg(R1) / Nin 2x100 mg(R2)
Started232324
Completed232324
Not completed000
Period 2 Including Washout
Participant flow — Period 2 Including Washout
MilestoneNin 2x100 mg(R1) / Nin 2x100 mg(R2) / Nin 1x200 mg(T)Nin 2x100 mg(R1) / Nin 1x200 mg(T) / Nin 2x100 mg(R2)Nin 1x200 mg(T) / Nin 2x100 mg(R1) / Nin 2x100 mg(R2)
Started232324
Completed232324
Not completed000
Period 3 Including Washout
Participant flow — Period 3 Including Washout
MilestoneNin 2x100 mg(R1) / Nin 2x100 mg(R2) / Nin 1x200 mg(T)Nin 2x100 mg(R1) / Nin 1x200 mg(T) / Nin 2x100 mg(R2)Nin 1x200 mg(T) / Nin 2x100 mg(R1) / Nin 2x100 mg(R2)
Started232324
Completed232324
Not completed000

Outcome measures

PrimaryAUC0-tz

Area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the last quantifiable data point (AUC0-tz). The unadjusted geometric mean (gMean) and geometric coefficient variation (gCV) was calculated for Test treatment (T), Reference treatment 1 (R1) and Reference treatment 2 (R2) separately.

Time frame:
-1:00 hour(h) before drug administration and 0:30h, 1:00h, 1:30h, 2:00h, 2:30h, 3:00h, 3:30h, 4:00h, 4:30h, 5:00h, 5:30h, 6:00h, 7:00h, 8:00h, 10:00h, 12:00h, 24:00h, 34:00h, 48:00h and 72:00h after drug administration.
Reported as:
Geometric mean · ng*h/mL
AUC0-tz
ng*h/mLNintedanib, Test Treatment (T)Nintedanib, Reference Treatment (R1)Nintedanib, Reference Treatment (R2)
AUC0-tz300 ± 38.8310 ± 37.6306 ± 36.2
Statistical analysis
  • Nintedanib, Test Treatment (T) vs Nintedanib, Reference Treatment (R1) vs Nintedanib, Reference Treatment (R2) · ANOVA · p = <0.0001 · Gmean ratio: 97.478 · 90% CI 94.545 to 100.502Relative bioavailability was estimated by the ratios of the gMean of nin Test treatment (T) divided by nin Reference treatment (R1 \& R2). Standard Error of the mean is actually the intra individual geometric coefficient variation (gCV).
PrimaryCmax

Maximum measured concentration of the analyte in plasma (Cmax). The unadjusted geometric mean (gMean) and geometric coefficient variation (gCV) was calculated for Test treatment (T), Reference 1 treatment (R1) and Reference 2 treatment (R2) separately.

Time frame:
-1:00 hour(h) before drug administration and 0:30h, 1:00h, 1:30h, 2:00h, 2:30h, 3:00h, 3:30h, 4:00h, 4:30h, 5:00h, 5:30h, 6:00h, 7:00h, 8:00h, 10:00h, 12:00h, 24:00h, 34:00h, 48:00h and 72:00h after drug administration.
Reported as:
Geometric mean · ng/mL
Cmax
ng/mLNintedanib, Test Treatment (T)Nintedanib, Reference Treatment (R1)Nintedanib, Reference Treatment (R2)
Cmax39.3 ± 56.041.1 ± 43.439.8 ± 46.3
Statistical analysis
  • Nintedanib, Test Treatment (T) vs Nintedanib, Reference Treatment (R1) vs Nintedanib, Reference Treatment (R2) · ANOVA · p = <0.0001 · Gmean ratio: 97.004 · 90% CI 90.948 to 103.463Relative bioavailability was estimated by the ratios of the gMean of nin Test treatment (T) divided by nin Reference treatment (R1 \& R2). Standard Error of the mean is actually the intra individual geometric coefficient variation (gCV).
SecondaryAUC0-inf

Area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity (AUC0-inf). The unadjusted geometric mean (gMean) and geometric coefficient variation (gCV) was calculated for Test treatment (T), Reference 1 treatment (R1) and Reference 2 treatment (R2) separately.

Time frame:
-1:00 hour(h) before drug administration and 0:30h, 1:00h, 1:30h, 2:00h, 2:30h, 3:00h, 3:30h, 4:00h, 4:30h, 5:00h, 5:30h, 6:00h, 7:00h, 8:00h, 10:00h, 12:00h, 24:00h, 34:00h, 48:00h and 72:00h after drug administration.
Reported as:
Geometric mean · ng*h/mL
AUC0-inf
ng*h/mLNintedanib, Test Treatment (T)Nintedanib, Reference Treatment (R1)Nintedanib, Reference Treatment (R2)
AUC0-inf311 ± 38.8322 ± 37.7319 ± 36.4
Statistical analysis
  • Nintedanib, Test Treatment (T) vs Nintedanib, Reference Treatment (R1) vs Nintedanib, Reference Treatment (R2) · ANOVA · p = <0.0001 · Gmean ratio: 97.149 · 90% CI 94.223 to 100.166Relative bioavailability was estimated by the ratios of the gMean of nin Test treatment (T) divided by nin Reference treatment (R1 \& R2). Standard Error of the mean is actually the intra individual geometric coefficient variation (gCV).

Adverse events

Collected over From first drug administration until 12 days after the last drug administration of nintedanib, ie., upto 16 days.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Nintedanib, Test Treatment (T)—0/70 (0%)24/70 (34.3%)
Nintedanib, Reference Treatment (R1 & R2)—0/70 (0%)29/70 (41.4%)
Most frequent other events
Most frequent other events
EventNintedanib, Test Treatment (T)Nintedanib, Reference Treatment (R1 & R2)
DiarrhoeaGastrointestinal disorders16/7020/70
HeadacheNervous system disorders7/707/70
NauseaGastrointestinal disorders4/706/70
NasopharyngitisInfections and infestations2/704/70

Baseline characteristics

Treated Set (TS): This analysis set included all 70 subjects (that is, all subjects who received at least 1 dose of study medication).

Age, Continuous
Age, Continuous(Years)Nin 2x100 mg(R1) / Nin 2x100 mg(R2) / Nin 1x200 mg(T)Nin 2x100 mg(R1) / Nin 1x200 mg(T) / Nin 2x100 mg(R2)Nin 1x200 mg(T) / Nin 2x100 mg(R1) / Nin 2x100 mg(R2)Total
Mean34.0 ± 10.336.6 ± 9.531.6 ± 7.234.0 ± 9.2
Gender
Gender(Participants)Nin 2x100 mg(R1) / Nin 2x100 mg(R2) / Nin 1x200 mg(T)Nin 2x100 mg(R1) / Nin 1x200 mg(T) / Nin 2x100 mg(R2)Nin 1x200 mg(T) / Nin 2x100 mg(R1) / Nin 2x100 mg(R2)Total
Female0000
Male23232470
08

Study locations

1 site
  • Boehringer Ingelheim Investigational Site
    Biberach, Germany
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2015, a primary completion of Nov 2015 and a completion of Nov 2015. It does not say whether these dates are actual or estimated.

Results were first posted in Jan 2017, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 8, 2015
First posted
Oct 9, 2015
Start
Aug 2015
Primary completionActual
Nov 2015
CompletionActual
Nov 2015
Results first posted
Jan 5, 2017
Last update
Jan 5, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 5, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02572752
Responsible party
Sponsor
First posted
Oct 9, 2015
Start date
Aug 2015
Primary completion
Nov 2015
Completion
Nov 2015
Results posted
Jan 5, 2017
Last update
Jan 5, 2017

Study contacts

Boehringer Ingelheim
study chair · Boehringer Ingelheim
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nintedanib

Start the discussion